- Resverlogix (RVX) has initiated the first Brazilian and a second Canadian site for its Phase 2b clinical trial for the treatment of COVID-19
- Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study
- The study aims to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19
- Apabetalone can address both the viral and the more deadly inflammatory aspects of COVID-19
- The company is prepping up for a third Canadian site in Toronto and five sites in Brazil
- Resverlogix is a late-stage biotechnology company and the world leader in epigenetics, or gene regulation
- Resverlogix (RVX) is trading flat at 73 cents at 12:35 PM EST
Resverlogix (RVX) has announced additional sites for its Phase 2b clinical trial of apabetalone as a treatment for COVID-19.
Donald J. McCaffrey, President & CEO of Resverlogix sat down with Shoran Devi to discuss the study.
Apabetalone is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. Epigenetics is the study of how cells control gene activity without changing the DNA sequence.
The company is now prepping up for a third Canadian site in Toronto and five sites in Brazil.
Study details
Resverlogix is conducting a randomized, open-label clinical study. The trial participants will either receive twice-daily oral doses of apabetalone or, alternatively, the standard care alone.
The company anticipates enrolling a total of 100 patients over the coming weeks, at multiple sites in Brazil and Canada.
Apabetalone’s unique dual epigenetic mechanism
As part of its ongoing efforts to combat the ongoing pandemic, Resverlogix is advancing the clinical development of apabetalone to aid in its treatment.
According to Resverlogix, apabetalone has the potential to help stop disease progression by regulating the expression of disease and inflammation-causing genes, without altering DNA.
Through this mechanism, apabetalone can address both the viral and the more deadly inflammatory aspects of COVID-19.
Resverlogix is a late-stage biotechnology company and the world leader in epigenetics, or gene regulation.
Resverlogix (RVX) is trading flat at 73 cents at 12:35 PM EST.
